Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,816 across all filing types
Latest filing 2024-06-12 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2024-06-12 English
6-K
Foreign Filer Report
2024-06-11 English
Director's Dealing 2024
Director's Dealing Classification · 1% confidence The document explicitly states it discloses transactions made by managerial employees and their closely associated persons in Genmab A/S shares, referencing Article 19 of Regulation No. 596/2014 (Market Abuse Regulation). This type of filing, detailing insider trading or transactions by management/directors, directly corresponds to the definition of Director's Dealing (DIRS). Although the document mentions an attachment, the core content is the disclosure itself, not just an announcement of a report (RPA/RNS). The subject matter is highly specific to insider transactions, making DIRS the most accurate classification over the general RNS fallback.
2024-06-11 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 1% confidence The document is a formal disclosure of share transactions made by a person discharging managerial responsibilities (a Board Member) at Genmab A/S. It explicitly cites Article 19 of Regulation No. 596/2014 (Market Abuse Regulation), which is the standard regulatory framework for reporting insider/director dealings. The content provides specific details of the transaction, including the name of the director, the nature of the transaction (sale of shares), price, volume, and the date of the trade. This fits the definition of 'Director's Dealing' (DIRS).
2024-06-11 English
6-K
Foreign Filer Report
2024-06-10 English
Transaction in Own Shares 2024
Transaction in Own Shares Classification · 1% confidence The document text explicitly details 'Transactions in Connection with Share Buy-back Program' executed between specific dates (June 3, 2024, to June 7, 2024). It provides detailed tables of shares bought and the total value. This activity directly relates to the company managing its own shares, which corresponds to the definition of 'Transaction in Own Shares'. The filing type code for this activity is POS.
2024-06-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.